Modality
Fusion Protein
MOA
PD-1i
Target
TIGIT
Pathway
Angiogenesis
LNFSGSHCC
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
~Feb 2020
→ ~May 2021
Phase 3
Aug 2021
→ Jul 2028
Phase 3Current
NCT04542859
732 pts·HCC
2025-02→TBD·Completed
NCT06488936
752 pts·LN
2022-10→2028-07·Terminated
NCT04043056
2,026 pts·HCC
2021-08→2025-06·Not yet recruiting
3,510 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-189mo agoPh3 Readout· HCC
2028-07-162.3y awayPh3 Readout· LN
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Not yet…
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2025-06-18 · 9mo ago
HCC
Ph3 Readout
2028-07-16 · 2.3y away
LN
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04542859 | Phase 3 | HCC | Completed | 732 | LiverFat |
| NCT06488936 | Phase 3 | LN | Terminated | 752 | eGFR |
| NCT04043056 | Phase 3 | HCC | Not yet recr... | 2026 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |